Abstract
The SS1P immunotoxin is combined with immunomodulatory therapy in order to improve its efficacy in human mesothelioma (Hassan et al., this issue).
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Comment
MeSH terms
-
Antibodies, Monoclonal / therapeutic use*
-
Female
-
GPI-Linked Proteins / immunology*
-
Humans
-
Immunosuppression Therapy*
-
Male
-
Mesothelin
-
Mesothelioma / immunology*
-
Mesothelioma / therapy*
-
Peritoneal Neoplasms / immunology*
-
Peritoneal Neoplasms / therapy*
Substances
-
Antibodies, Monoclonal
-
GPI-Linked Proteins
-
SS1(dsFv)PE38
-
Mesothelin